The launch of Atrium Therapeutics marks a pivotal shift in the landscape of cardiovascular medicine, emerging as a specialized spin-off following Novartis’s multi-billion dollar acquisition of Avidity. Led by Kathleen Gallagher, the former Chief Program Officer of Avidity, the company is tasked with advancing a high-stakes pipeline focused on genetic cardiomyopathies. By leveraging the pioneering Antibody Oligonucleotide Conjugate (AOC) platform, Atrium seeks to solve the long-standing challenge of delivering RNA therapies directly to the heart, potentially transforming the lives of patients with rare, life-threatening conditions.
This discussion explores the mechanics of AOC technology, the clinical roadmaps for candidates ATR 1072 and ATR 1086, and the strategic complexities of managing a $270 million startup while maintaining significant pharmaceutical partnerships.
RNA therapies traditionally struggle to reach tissues outside the liver. How do antibody oligonucleotide conjugates overcome this delivery barrier, and what specific technical hurdles do you face when engineering these molecules to target cardiac tissue specifically?
The primary challenge with traditional RNA therapies is their natural tendency to accumulate in the liver, which acts as a filter, preventing the medicine from reaching other vital organs. Antibody oligonucleotide conjugates, or AOCs, solve this by using the precision of a monoclonal antibody as a delivery vehicle to escort the RNA payload directly to the desired tissue. In the case of cardiac tissue, we engineer the antibody to recognize and bind to specific receptors on heart muscle cells, ensuring the therapy is internalized where it can do the most good. This process requires a delicate balance; we must ensure the linkage between the antibody and the RNA is stable enough to survive the bloodstream but capable of releasing the therapeutic cargo once inside the cell. Our goal is to move beyond the liver-centric model and prove that we can achieve meaningful concentrations of RNA in the heart to address the underlying drivers of genetic disease.
PRKAG2 syndrome currently lacks FDA-approved treatments despite its severe impact on cardiac health. With an investigational new drug application expected later this year for ATR 1072, what does the clinical roadmap look like, and how will you measure initial efficacy in these rare cardiomyopathy patients?
PRKAG2 syndrome is a devastating inherited disorder where gene mutations lead to early-onset cardiomyopathy, and currently, patients have no approved options to treat the cause. Our roadmap for ATR 1072 is aggressive because the need is so urgent, with our team currently finalized for an Investigational New Drug application in the second half of this year. Once we move into the clinic, our primary focus will be on safety, but we will also look closely at biomarkers that indicate whether we are successfully modulating the PRKAG2 gene activity. We intend to use advanced cardiac imaging and specific protein measurements to see if the therapy is slowing or reversing the structural changes in the heart. This data will be critical in demonstrating to regulators that we can effectively target the biological source of the disease rather than just managing the symptoms of heart failure.
PLN cardiomyopathy carries a significant risk for heart failure and sudden cardiac death. As you initiate preclinical research on ATR 1086, what are the primary biological drivers you are targeting, and what specific milestones must the program hit to ensure a successful regulatory submission by next year?
PLN cardiomyopathy is driven by mutations in the phospholamban gene, which disrupts how calcium is handled within heart cells, leading to lethal arrhythmias and progressive heart failure. With ATR 1086, our therapeutic objective is to use RNA to correct this calcium regulation, essentially “resetting” the biological machinery of the heart muscle. To hit our target of a regulatory submission by next year, we must first complete comprehensive preclinical toxicology studies and dose-ranging trials to ensure the therapy is both safe and effective in animal models. We are also focusing on refining our manufacturing processes to produce the AOC at a scale that meets clinical standards. Every milestone we hit in the lab this year is designed to build a robust data package that proves to the FDA that ATR 1086 can safely stabilize the heart’s electrical and mechanical functions.
Launching a biotech with $270 million provides a significant runway but also high expectations. How will you prioritize this capital across the cardiovascular pipeline, and what is the strategic value of maintaining independent research collaborations with major pharmaceutical partners like Bristol Myers Squibb and Eli Lilly?
Starting with $270 million in cash and equivalents gives us the financial independence to move our lead programs, ATR 1072 and ATR 1086, through the most expensive phases of early development without immediate pressure to raise more capital. We are prioritizing our spending on the high-cost requirements of clinical manufacturing and the initiation of our first human trials, which are the most significant value-inflection points for the company. Simultaneously, maintaining our inherited collaborations with Bristol Myers Squibb and Eli Lilly is a strategic cornerstone for us. These partnerships provide not only financial support but also a massive amount of technical validation and shared expertise. By keeping these relationships independent, we can focus our internal resources on our rare disease pipeline while leveraging the global reach of these partners to explore broader applications of the AOC platform.
Transitioning a specialized portfolio into a standalone entity involves complex organizational shifts. Having moved from a leadership role in a parent company to heading this new venture, what were the most critical steps in establishing independence, and how do you maintain technical continuity during such a transition?
The most critical step in establishing Atrium as a standalone entity was ensuring a clean separation of assets and intellectual property during the Novartis acquisition, which resulted in us trading under our own symbol, “RNAM,” on the Nasdaq. We had to move quickly to secure our $270 million capital base and establish our own corporate governance, including the appointment of Sarah Boyce as our chair. To maintain technical continuity, we kept the core scientific team that pioneered the AOC platform, ensuring that the institutional knowledge regarding cardiac targeting wasn’t lost during the shuffle. We view this transition not as a start from scratch, but as a focused refinement; we are taking the best parts of our history at Avidity and applying them exclusively to the unique challenges of the heart. This allows us to move with the speed of a startup while possessing the technological maturity of an established platform company.
What is your forecast for the field of precision cardiology?
I believe the field of precision cardiology is on the verge of a transformation similar to what we saw in oncology over the last decade, where we move away from “one-size-fits-all” treatments like beta-blockers and toward gene-specific therapies. Within the next few years, I expect we will see the first successful clinical proof-of-concept for RNA delivery to the heart, which will open the floodgates for treating dozens of previously “undruggable” genetic heart conditions. As genetic testing becomes more routine in cardiology clinics, we will be able to identify patients earlier and intervene with therapies like AOCs before irreversible heart damage occurs. Ultimately, our goal is to reach a point where a patient’s specific genetic mutation dictates their treatment plan, leading to significantly better outcomes and a reduction in the need for heart transplants. Precision medicine will no longer be a niche area of research; it will become the standard of care for cardiovascular health.
